tiprankstipranks
Actinogen Medical Touts Xanamem’s Potential in Conference
Company Announcements

Actinogen Medical Touts Xanamem’s Potential in Conference

Actinogen Medical Limited (AU:ACW) has released an update.

Pick the best stocks and maximize your portfolio:

Actinogen Medical’s CEO Dr. Steven Gourlay highlighted the company’s promising drug Xanamem at the Pitt Street Research Conference, which aims to treat depression and Alzheimer’s disease by controlling brain cortisol. With positive results from recent clinical trials, the company looks forward to the potential of Xanamem as it enters late-phase testing. This innovative treatment addresses a significant unmet need for new therapies in neurological and psychiatric diseases.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Sees Change in Major Shareholder Stake
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Lists 59.5 Million Shares on ASX
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Lists New Trading Options on ASX
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App